Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Carboplatino y paclitaxel u oxaliplatino y capecitabina con o sin bevacizumab como terapia de primera línea en el tratamiento de pacientes con cáncer epitelial de ovario o de trompas de Falopio en estadio II-IV recién diagnosticado o estadio I recidivante

16 de noviembre de 2026 actualizado por: National Cancer Institute (NCI)

Un ensayo de fase III multicéntrico intergrupal de GCIG de carboplatino de etiqueta abierta y paclitaxel +/- agente suministrado por el NCI: bevacizumab (NSC n.º 704865) en comparación con oxaliplatino y capecitabina +/- bevacizumab como quimioterapia de primera línea en pacientes con cáncer epitelial mucinoso de ovario o de trompas de Falopio (MEOC)

This randomized phase III trial studies carboplatin given together with paclitaxel with or without bevacizumab to see how well it works compared with oxaliplatin given together with capecitabine with or without bevacizumab as first-line therapy in treating patients with newly diagnosed stage II-IV, or recurrent (has come back) stage I epithelial ovarian or fallopian tube cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known which regimen of combination chemotherapy given together with or without bevacizumab is more effective in treating epithelial ovarian cancer or fallopian tube cancer.

Descripción general del estudio

Descripción detallada

PRIMARY OBJECTIVES:

I. To determine if capecitabine and oxaliplatin reduces the death rate compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.

II. To determine if bevacizumab reduces the death rate compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.

SECONDARY OBJECTIVES:

I. To determine if capecitabine and oxaliplatin increases the duration of progression-free survival (PFS) compared to carboplatin and paclitaxel in women with mucinous adenocarcinoma of the ovary or fallopian tube.

II. To determine if bevacizumab increases the duration of PFS compared to no bevacizumab in women with mucinous adenocarcinoma of the ovary or fallopian tube.

III. To compare the response rates for capecitabine and oxaliplatin versus carboplatin and paclitaxel in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.

IV. To compare the response rates for bevacizumab versus no bevacizumab in patients with mucinous adenocarcinoma of the ovary or fallopian tube with measurable disease after initial tumor reductive surgery.

V. To determine the nature and degree of toxicity of capecitabine and oxaliplatin compared with that of carboplatin and paclitaxel in this cohort of patients.

VI. To determine the nature and degree of toxicity of bevacizumab in this cohort of patients.

VII. To compare capecitabine and oxaliplatin versus carboplatin and paclitaxel with respect to changes in patient reported neurotoxicity.

VIII. To determine the impact on quality of life (QOL, as measured by the Functional Assessment of Cancer Therapy-Ovarian [FACT-O] Trial Outcome Index [TOI]) following treatment with the above regimens.

TERTIARY OBJECTIVES:

I. To collect fixed and/or frozen tissue and whole blood for future research studies.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

ARM I: Patients receive carboplatin intravenously (IV) over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine orally (PO) twice daily (BID) on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

ARM III: Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.

ARM IV: Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.

After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

50

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • University of Alabama at Birmingham Cancer Center
      • Mobile, Alabama, Estados Unidos, 36688
        • University of South Alabama Mitchell Cancer Institute
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85013
        • Saint Joseph's Hospital and Medical Center
    • Arkansas
      • Jonesboro, Arkansas, Estados Unidos, 72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Burbank, California, Estados Unidos, 91505
        • Providence Saint Joseph Medical Center/Disney Family Cancer Center
      • Castro Valley, California, Estados Unidos, 94546
        • East Bay Radiation Oncology Center
      • Castro Valley, California, Estados Unidos, 94546
        • Valley Medical Oncology Consultants-Castro Valley
      • Emeryville, California, Estados Unidos, 94608
        • Bay Area Breast Surgeons Inc
      • Emeryville, California, Estados Unidos, 94608
        • Epic Care Partners in Cancer Care
      • Fremont, California, Estados Unidos, 94538
        • Valley Medical Oncology Consultants-Fremont
      • Los Angeles, California, Estados Unidos, 90033
        • USC / Norris Comprehensive Cancer Center
      • Los Angeles, California, Estados Unidos, 90033
        • Los Angeles General Medical Center
      • Martinez, California, Estados Unidos, 94553-3156
        • Contra Costa Regional Medical Center
      • Mountain View, California, Estados Unidos, 94040
        • El Camino Hospital
      • Oakland, California, Estados Unidos, 94609
        • Alta Bates Summit Medical Center - Summit Campus
      • Oakland, California, Estados Unidos, 94609
        • Hematology and Oncology Associates-Oakland
      • Oakland, California, Estados Unidos, 94609
        • Tom K Lee Inc
      • Oakland, California, Estados Unidos, 94609
        • Bay Area Tumor Institute
      • Oakland, California, Estados Unidos, 94602
        • Wilma Chan Highland Hospital
      • Orange, California, Estados Unidos, 92868
        • UC Irvine Health/Chao Family Comprehensive Cancer Center
      • San Pablo, California, Estados Unidos, 94806
        • Doctors Medical Center- JC Robinson Regional Cancer Center
      • Sylmar, California, Estados Unidos, 91342
        • Olive View-University of California Los Angeles Medical Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80012
        • The Medical Center of Aurora
      • Aurora, Colorado, Estados Unidos, 80045
        • UCHealth University of Colorado Hospital
      • Boulder, Colorado, Estados Unidos, 80303
        • Boulder Community Foothills Hospital
      • Colorado Springs, Colorado, Estados Unidos, 80907
        • Penrose-Saint Francis Healthcare
      • Denver, Colorado, Estados Unidos, 80218
        • Presbyterian - Saint Lukes Medical Center - Health One
      • Denver, Colorado, Estados Unidos, 80220
        • Rose Medical Center
      • Denver, Colorado, Estados Unidos, 80222
        • Western States Cancer Research NCORP
      • Denver, Colorado, Estados Unidos, 80218
        • Saint Joseph Hospital - Cancer Centers of Colorado
      • Denver, Colorado, Estados Unidos, 80210
        • AdventHealth Porter
      • Englewood, Colorado, Estados Unidos, 80113
        • Swedish Medical Center
      • Fort Collins, Colorado, Estados Unidos, 80524
        • Poudre Valley Hospital
      • Grand Junction, Colorado, Estados Unidos, 81501
        • Saint Mary's Hospital and Regional Medical Center
      • Greeley, Colorado, Estados Unidos, 80631
        • Banner North Colorado Medical Center
      • Lakewood, Colorado, Estados Unidos, 80228
        • CommonSpirit Saint Anthony Hospital Cancer Center
      • Littleton, Colorado, Estados Unidos, 80122
        • AdventHealth Littleton
      • Lone Tree, Colorado, Estados Unidos, 80124
        • Sky Ridge Medical Center
      • Longmont, Colorado, Estados Unidos, 80501
        • Longmont United Hospital
      • Loveland, Colorado, Estados Unidos, 80539
        • Banner North Colorado Medical Center - Loveland Campus
      • Parker, Colorado, Estados Unidos, 80138
        • AdventHealth Parker
      • Pueblo, Colorado, Estados Unidos, 81004
        • Saint Mary Corwin Medical Center
      • Thornton, Colorado, Estados Unidos, 80229
        • North Suburban Medical Center
      • Wheat Ridge, Colorado, Estados Unidos, 80401
        • Intermountain Health Lutheran Hospital
    • Connecticut
      • Hartford, Connecticut, Estados Unidos, 06102
        • Hartford Hospital
      • New Britain, Connecticut, Estados Unidos, 06050
        • The Hospital of Central Connecticut
      • Stamford, Connecticut, Estados Unidos, 06904
        • Stamford Hospital/Bennett Cancer Center
    • Delaware
      • Lewes, Delaware, Estados Unidos, 19958
        • Beebe Medical Center
      • Newark, Delaware, Estados Unidos, 19718
        • Christiana Care Health System-Christiana Hospital
    • Florida
      • Gainesville, Florida, Estados Unidos, 32610
        • UF Health Cancer Institute - Gainesville
      • Orlando, Florida, Estados Unidos, 32803
        • AdventHealth Orlando
    • Georgia
      • Augusta, Georgia, Estados Unidos, 30912
        • Augusta University Medical Center
      • Columbus, Georgia, Estados Unidos, 31904
        • John B Amos Cancer Center
      • Gainesville, Georgia, Estados Unidos, 30501
        • Northeast Georgia Medical Center-Gainesville
      • Savannah, Georgia, Estados Unidos, 31405
        • Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
    • Hawaii
      • Honolulu, Hawaii, Estados Unidos, 96813
        • Queen's Medical Center
      • Honolulu, Hawaii, Estados Unidos, 96813
        • University of Hawaii Cancer Center
      • Honolulu, Hawaii, Estados Unidos, 96826
        • Kapiolani Medical Center for Women and Children
    • Illinois
      • Bloomington, Illinois, Estados Unidos, 61704
        • Illinois CancerCare-Bloomington
      • Bloomington, Illinois, Estados Unidos, 61701
        • OSF Saint Joseph Medical Center
      • Canton, Illinois, Estados Unidos, 61520
        • Illinois CancerCare-Canton
      • Canton, Illinois, Estados Unidos, 61520
        • Graham Hospital Association
      • Carthage, Illinois, Estados Unidos, 62321
        • Illinois CancerCare-Carthage
      • Carthage, Illinois, Estados Unidos, 62321
        • Memorial Hospital
      • Chicago, Illinois, Estados Unidos, 60637
        • University of Chicago Comprehensive Cancer Center
      • Decatur, Illinois, Estados Unidos, 62526
        • Heartland Cancer Research NCORP
      • Eureka, Illinois, Estados Unidos, 61530
        • Illinois CancerCare-Eureka
      • Eureka, Illinois, Estados Unidos, 61530
        • Eureka Hospital
      • Galesburg, Illinois, Estados Unidos, 61401
        • Illinois CancerCare-Galesburg
      • Havana, Illinois, Estados Unidos, 62644
        • Mason District Hospital
      • Havana, Illinois, Estados Unidos, 62644
        • Illinois CancerCare-Havana
      • Hinsdale, Illinois, Estados Unidos, 60521
        • Sudarshan K Sharma MD Limited-Gynecologic Oncology
      • Kewanee, Illinois, Estados Unidos, 61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb, Illinois, Estados Unidos, 61455
        • Illinois CancerCare-Macomb
      • Macomb, Illinois, Estados Unidos, 61455
        • Mcdonough District Hospital
      • Monmouth, Illinois, Estados Unidos, 61462
        • Illinois CancerCare-Monmouth
      • Monmouth, Illinois, Estados Unidos, 61462
        • Holy Family Medical Center
      • Normal, Illinois, Estados Unidos, 61761
        • Carle Cancer Institute Normal
      • Normal, Illinois, Estados Unidos, 61761
        • Illinois CancerCare-Community Cancer Center
      • Normal, Illinois, Estados Unidos, 61761
        • Carle BroMenn Medical Center
      • Ottawa, Illinois, Estados Unidos, 61350
        • Illinois CancerCare-Ottawa Clinic
      • Ottawa, Illinois, Estados Unidos, 61350
        • Ottawa Regional Hospital and Healthcare Center
      • Pekin, Illinois, Estados Unidos, 61554
        • Illinois CancerCare-Pekin
      • Pekin, Illinois, Estados Unidos, 61554
        • OSF Saint Francis Radiation Oncology at Pekin
      • Peoria, Illinois, Estados Unidos, 61636
        • Methodist Medical Center of Illinois
      • Peoria, Illinois, Estados Unidos, 61637
        • OSF Saint Francis Medical Center
      • Peoria, Illinois, Estados Unidos, 61615
        • Illinois CancerCare-Peoria
      • Peoria, Illinois, Estados Unidos, 61614
        • Proctor Hospital
      • Peru, Illinois, Estados Unidos, 61354
        • Illinois CancerCare-Peru
      • Peru, Illinois, Estados Unidos, 61354
        • Illinois Valley Hospital
      • Princeton, Illinois, Estados Unidos, 61356
        • Illinois CancerCare-Princeton
      • Princeton, Illinois, Estados Unidos, 61356
        • Perry Memorial Hospital
      • Rockford, Illinois, Estados Unidos, 61104
        • Swedish American Hospital
      • Spring Valley, Illinois, Estados Unidos, 61362
        • Illinois CancerCare-Spring Valley
    • Indiana
      • Elkhart, Indiana, Estados Unidos, 46515
        • Elkhart General Hospital
      • Elkhart, Indiana, Estados Unidos, 46514
        • Michiana Hematology Oncology PC-Elkhart
      • Elkhart, Indiana, Estados Unidos, 46514-2098
        • Elkhart Clinic
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University/Melvin and Bren Simon Cancer Center
      • Indianapolis, Indiana, Estados Unidos, 46260
        • Ascension Saint Vincent Indianapolis Hospital
      • Kokomo, Indiana, Estados Unidos, 46904
        • Community Howard Regional Health
      • La Porte, Indiana, Estados Unidos, 46350
        • IU Health La Porte Hospital
      • Mishawaka, Indiana, Estados Unidos, 46545
        • Michiana Hematology Oncology PC-Mishawaka
      • Mishawaka, Indiana, Estados Unidos, 46545
        • Cancer Care Partners LLC
      • Mishawaka, Indiana, Estados Unidos, 46545
        • Saint Joseph Regional Medical Center-Mishawaka
      • Plymouth, Indiana, Estados Unidos, 46563
        • Michiana Hematology Oncology PC-Plymouth
      • South Bend, Indiana, Estados Unidos, 46601
        • Memorial Hospital of South Bend
      • South Bend, Indiana, Estados Unidos, 46628
        • Northern Indiana Cancer Research Consortium
      • South Bend, Indiana, Estados Unidos, 46617
        • South Bend Clinic
      • Westville, Indiana, Estados Unidos, 46391
        • Michiana Hematology Oncology PC-Westville
    • Iowa
      • Clive, Iowa, Estados Unidos, 50325
        • Mercy Cancer Center-West Lakes
      • Clive, Iowa, Estados Unidos, 50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Estados Unidos, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Estados Unidos, 50316
        • Iowa Lutheran Hospital
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa-Wide Oncology Research Coalition NCORP
      • Des Moines, Iowa, Estados Unidos, 50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines, Iowa, Estados Unidos, 50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Sioux City, Iowa, Estados Unidos, 51101
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, Estados Unidos, 51102
        • Mercy Medical Center-Sioux City
      • Sioux City, Iowa, Estados Unidos, 51104
        • Saint Luke's Regional Medical Center
      • West Des Moines, Iowa, Estados Unidos, 50266-7700
        • Methodist West Hospital
      • West Des Moines, Iowa, Estados Unidos, 50266
        • Mercy Medical Center-West Lakes
    • Kentucky
      • Edgewood, Kentucky, Estados Unidos, 41017
        • Saint Elizabeth Healthcare Edgewood
      • Lexington, Kentucky, Estados Unidos, 40536
        • University of Kentucky/Markey Cancer Center
      • Pikeville, Kentucky, Estados Unidos, 41501
        • Pikeville Medical Center
    • Louisiana
      • Lafayette, Louisiana, Estados Unidos, 70503
        • Cancer Center of Acadiana
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Ochsner Medical Center Jefferson
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21204
        • Greater Baltimore Medical Center
      • Bethesda, Maryland, Estados Unidos, 20889-5600
        • Walter Reed National Military Medical Center
      • Elkton, Maryland, Estados Unidos, 21921
        • Christiana Care - Union Hospital
    • Massachusetts
      • Springfield, Massachusetts, Estados Unidos, 01199
        • Baystate Medical Center
    • Michigan
      • Escanaba, Michigan, Estados Unidos, 49829
        • OSF Saint Francis Hospital and Medical Group
      • Kalamazoo, Michigan, Estados Unidos, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Estados Unidos, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, Estados Unidos, 49048
        • Beacon Kalamazoo
      • Niles, Michigan, Estados Unidos, 49120
        • Corewell Health Lakeland Hospitals - Niles Hospital
      • Saint Joseph, Michigan, Estados Unidos, 49085
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
      • Saint Joseph, Michigan, Estados Unidos, 49085
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39216
        • University of Mississippi Medical Center
    • Missouri
      • Cape Girardeau, Missouri, Estados Unidos, 63703
        • Mercy Cancer Center - Cape Girardeau
      • Jefferson City, Missouri, Estados Unidos, 65109
        • MU Health Care Goldschmidt Cancer Center
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, Estados Unidos, 63131
        • Missouri Baptist Medical Center
    • Montana
      • Billings, Montana, Estados Unidos, 59101
        • Billings Clinic Cancer Center
      • Billings, Montana, Estados Unidos, 59101
        • Saint Vincent Healthcare
      • Billings, Montana, Estados Unidos, 59102
        • Montana Cancer Consortium NCORP
      • Billings, Montana, Estados Unidos, 59102
        • Saint Vincent Frontier Cancer Center
      • Bozeman, Montana, Estados Unidos, 59715
        • Bozeman Health Deaconess Hospital
      • Butte, Montana, Estados Unidos, 59701
        • Saint James Community Hospital and Cancer Treatment Center
      • Great Falls, Montana, Estados Unidos, 59405
        • Great Falls Clinic
      • Great Falls, Montana, Estados Unidos, 59405
        • Benefis Sletten Cancer Institute
      • Havre, Montana, Estados Unidos, 59501
        • Northern Montana Hospital
      • Helena, Montana, Estados Unidos, 59601
        • Saint Peter's Community Hospital
      • Kalispell, Montana, Estados Unidos, 59901
        • Glacier Oncology PLLC
      • Kalispell, Montana, Estados Unidos, 59901
        • Kalispell Medical Oncology
      • Kalispell, Montana, Estados Unidos, 59901
        • Logan Health Medical Center
      • Missoula, Montana, Estados Unidos, 59802
        • Saint Patrick Hospital - Community Hospital
      • Missoula, Montana, Estados Unidos, 59802
        • Montana Cancer Specialists
    • Nebraska
      • Omaha, Nebraska, Estados Unidos, 68114
        • Nebraska Methodist Hospital
    • Nevada
      • Las Vegas, Nevada, Estados Unidos, 89106
        • Women's Cancer Center of Nevada
    • New Jersey
      • Camden, New Jersey, Estados Unidos, 08103
        • Cooper Hospital University Medical Center
      • Mount Holly, New Jersey, Estados Unidos, 08060
        • Virtua Memorial
      • Voorhees Township, New Jersey, Estados Unidos, 08043
        • Virtua Voorhees
    • New Mexico
      • Albuquerque, New Mexico, Estados Unidos, 87106
        • Southwest Gynecologic Oncology Associates Inc
      • Albuquerque, New Mexico, Estados Unidos, 87106
        • University of New Mexico Cancer Center
    • New York
      • Stony Brook, New York, Estados Unidos, 11794
        • Stony Brook University Medical Center
      • Syracuse, New York, Estados Unidos, 13210
        • State University of New York Upstate Medical University
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27599
        • UNC Lineberger Comprehensive Cancer Center
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center
      • Goldsboro, North Carolina, Estados Unidos, 27534
        • Wayne Memorial Hospital
      • Hendersonville, North Carolina, Estados Unidos, 28792
        • AdventHealth Hendersonville
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Wake Forest University Health Sciences
      • Winston-Salem, North Carolina, Estados Unidos, 27104
        • Southeast Clinical Oncology Research Consortium NCORP
    • North Dakota
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Sanford Bismarck Medical Center
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Mid Dakota Clinic
      • Bismarck, North Dakota, Estados Unidos, 58501
        • Saint Alexius Medical Center
    • Ohio
      • Akron, Ohio, Estados Unidos, 44304
        • Summa Health System - Akron Campus
      • Bellefontaine, Ohio, Estados Unidos, 43311
        • Mary Rutan Hospital
      • Canton, Ohio, Estados Unidos, 44710
        • Aultman Health Foundation
      • Chillicothe, Ohio, Estados Unidos, 45601
        • Adena Regional Medical Center
      • Cincinnati, Ohio, Estados Unidos, 45219
        • University of Cincinnati Cancer Center-UC Medical Center
      • Cincinnati, Ohio, Estados Unidos, 45220
        • Good Samaritan Hospital - Cincinnati
      • Cincinnati, Ohio, Estados Unidos, 45242
        • Bethesda North Hospital
      • Cleveland, Ohio, Estados Unidos, 44106
        • Case Western Reserve University
      • Cleveland, Ohio, Estados Unidos, 44109
        • MetroHealth Medical Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic Foundation
      • Cleveland, Ohio, Estados Unidos, 44111
        • Cleveland Clinic Cancer Center/Fairview Hospital
      • Columbus, Ohio, Estados Unidos, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University Comprehensive Cancer Center
      • Columbus, Ohio, Estados Unidos, 43219
        • The Mark H Zangmeister Center
      • Columbus, Ohio, Estados Unidos, 43228
        • Doctors Hospital
      • Columbus, Ohio, Estados Unidos, 43213
        • Mount Carmel East Hospital
      • Columbus, Ohio, Estados Unidos, 43215
        • Grant Medical Center
      • Columbus, Ohio, Estados Unidos, 43222
        • Mount Carmel Health Center West
      • Columbus, Ohio, Estados Unidos, 43215
        • Columbus NCI Community Oncology Research Program
      • Delaware, Ohio, Estados Unidos, 43015
        • Grady Memorial Hospital
      • Kettering, Ohio, Estados Unidos, 45429
        • Kettering Medical Center
      • Lancaster, Ohio, Estados Unidos, 43130
        • Fairfield Medical Center
      • Marietta, Ohio, Estados Unidos, 45750
        • Marietta Memorial Hospital
      • Mayfield Heights, Ohio, Estados Unidos, 44124
        • Hillcrest Hospital Cancer Center
      • Mentor, Ohio, Estados Unidos, 44060
        • UH Seidman Cancer Center at Lake Health Mentor Campus
      • Mount Vernon, Ohio, Estados Unidos, 43050
        • Knox Community Hospital
      • Newark, Ohio, Estados Unidos, 43055
        • Licking Memorial Hospital
      • Portsmouth, Ohio, Estados Unidos, 45662
        • Southern Ohio Medical Center
      • Springfield, Ohio, Estados Unidos, 45504
        • Springfield Regional Medical Center
      • Westerville, Ohio, Estados Unidos, 43081
        • Saint Ann's Hospital
      • Zanesville, Ohio, Estados Unidos, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73104
        • University of Oklahoma Health Sciences Center
      • Tulsa, Oklahoma, Estados Unidos, 74146
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Pennsylvania
      • Abington, Pennsylvania, Estados Unidos, 19001
        • Jefferson Abington Hospital
      • Bethlehem, Pennsylvania, Estados Unidos, 18015
        • Saint Luke's University Hospital-Bethlehem Campus
      • Danville, Pennsylvania, Estados Unidos, 17822
        • Geisinger Medical Center
      • Hazleton, Pennsylvania, Estados Unidos, 18201
        • Geisinger Medical Center-Cancer Center Hazleton
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Hillman Cancer Center
      • State College, Pennsylvania, Estados Unidos, 16801
        • Geisinger Medical Group
      • Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
        • Geisinger Wyoming Valley/Henry Cancer Center
    • Rhode Island
      • Providence, Rhode Island, Estados Unidos, 02905
        • Women and Infants Hospital
    • South Carolina
      • Anderson, South Carolina, Estados Unidos, 29621
        • AnMed Health Cancer Center
      • Anderson, South Carolina, Estados Unidos, 29621
        • AnMed Health Hospital
      • Greenville, South Carolina, Estados Unidos, 29601
        • Saint Francis Hospital
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Spartanburg Medical Center
    • South Dakota
      • Sioux Falls, South Dakota, Estados Unidos, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Estados Unidos, 57104
        • Sanford Cancer Center Oncology Clinic
    • Tennessee
      • Knoxville, Tennessee, Estados Unidos, 37920
        • University of Tennessee - Knoxville
    • Texas
      • Dallas, Texas, Estados Unidos, 75235
        • Parkland Memorial Hospital
      • Dallas, Texas, Estados Unidos, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Galveston, Texas, Estados Unidos, 77555-0565
        • University of Texas Medical Branch
      • Houston, Texas, Estados Unidos, 77030
        • UT MD Anderson Cancer Center
      • Houston, Texas, Estados Unidos, 77030
        • Houston Methodist Hospital
      • Houston, Texas, Estados Unidos, 77030
        • Memorial Hermann Texas Medical Center
    • Virginia
      • Danville, Virginia, Estados Unidos, 24541
        • Danville Regional Medical Center
      • Fredericksburg, Virginia, Estados Unidos, 22408
        • Hematology Oncology Associates of Fredericksburg Inc
      • Lynchburg, Virginia, Estados Unidos, 24501
        • Centra Alan B Pearson Regional Cancer Center
    • Wisconsin
      • Green Bay, Wisconsin, Estados Unidos, 54301
        • Saint Vincent Hospital Cancer Center Green Bay
      • Green Bay, Wisconsin, Estados Unidos, 54303
        • Saint Vincent Hospital Cancer Center at Saint Mary's
      • Green Bay, Wisconsin, Estados Unidos, 54301-3526
        • Green Bay Oncology at Saint Vincent Hospital
      • La Crosse, Wisconsin, Estados Unidos, 54601
        • Gundersen Lutheran Medical Center
      • Manitowoc, Wisconsin, Estados Unidos, 54221
        • Holy Family Memorial Hospital
      • Marinette, Wisconsin, Estados Unidos, 54143
        • Bay Area Medical Center
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53215
        • Aurora Saint Luke's Medical Center
      • Milwaukee, Wisconsin, Estados Unidos, 53233
        • Aurora Sinai Medical Center
      • Oconto Falls, Wisconsin, Estados Unidos, 54154
        • Saint Vincent Hospital Cancer Center at Oconto Falls
      • Sheboygan, Wisconsin, Estados Unidos, 53081
        • Vince Lombardi Cancer Clinic-Sheboygan
      • Summit, Wisconsin, Estados Unidos, 53066
        • Aurora Medical Center in Summit
      • West Allis, Wisconsin, Estados Unidos, 53227
        • Aurora West Allis Medical Center
    • Wyoming
      • Casper, Wyoming, Estados Unidos, 82609
        • Rocky Mountain Oncology
      • Sheridan, Wyoming, Estados Unidos, 82801
        • Welch Cancer Center

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Patients with a histologic diagnosis of mucinous adenocarcinoma of the ovary or fallopian tube with either optimal (=< 1 cm residual disease) or suboptimal residual disease following initial surgery; patients may have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or no measurable disease
  • All patients must have had appropriate surgery including appendectomy (unless patient has history of prior appendectomy) for ovarian or fallopian tube carcinoma with appropriate tissue available for histologic evaluation to confirm diagnosis and stage
  • Patients must have stage II-IV disease (new or recurrent-chemonaïve; no brain metastasis) or recurrent stage I disease (chemonaïve)
  • Newly diagnosed patients must begin protocol therapy within 10 weeks of primary debulking; for stage I recurrent patients (chemonaïve), they should begin protocol therapy within 14 days of randomization
  • Patients must have a negative colonoscopy within 1 year of enrolling in the study
  • Absolute neutrophil count (ANC) >= 1,500/mcl
  • White blood cell (WBC) count >= 3,000/mcl
  • Platelets >= 100,000/mcl
  • Hemoglobin (Hgb) >= 10 g/dl (can be post transfusion)
  • Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN) OR creatinine clearance > 50 cc/min
  • Bilirubin =< 1.5 x ULN
  • Serum glutamic oxaloacetic transaminase (SGOT) =< to 2.5 x ULN
  • Alkaline phosphatase =< to 2.5 x ULN
  • Neuropathy (sensory and motor) =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1
  • Urine dipstick for proteinuria < 2+; if urine dipstick is >= 2+, 24 hour urine must demonstrate =< 1 g protein in 24 hours OR patients must have a urine protein-to-creatinine ratio (UPCR) < 1.0 mg/dL
  • Prothrombin time (PT) =< 1.5 x ULN
  • Activated prothrombin time (APTT) =< 1.5 x ULN
  • Patients of childbearing potential must agree to practice an effective form of birth control during study treatment and for six months after completion of treatment
  • Patients who have met the pre-entry requirements
  • Patients must have signed an approved informed consent and authorization permitting release of personal health information
  • Patients with Gynecologic Oncology Group (GOG) performance grade of 0, 1 or 2
  • Patients with life expectancy > 3 months

Exclusion Criteria:

  • Patients with known colon cancer or history of colon cancer
  • Patients with primary peritoneal carcinoma
  • Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last 5 years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
  • Patients who have received chemotherapy, radiotherapy or any investigational treatment for a gynecologic cancer (does include breast cancer) or colorectal cancer prior to enrollment
  • Patients with a major surgical procedure anticipated during the course of the study; this includes but is not limited to: abdominal surgery (laparotomy or laparoscopy) such as colostomy or enterostomy reversal, interval or secondary cytoreductive surgery, or second look surgery; please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures
  • Patients may have minor surgical procedures (i.e., mediport insertion) fine needle aspiration or core biopsies as long as it is performed > 7 days prior to the first date of bevacizumab therapy and there is no evidence of wound disruption or impaired healing
  • Patients with surgery (including open biopsy) within 4 weeks prior to anticipated first dose of bevacizumab (allowing for fact that bevacizumab can be omitted from first cycle of chemotherapy)
  • Patients with a history of abdominal fistula or perforation within the past 12 months
  • Patients with a current, serious, non-healing wound, ulcer, or bone fracture; patients with granulating incisions healing by secondary intention with no evidence of fascial dehiscence or infection are eligible but require weekly wound examinations
  • Patients with known hypersensitivity to Chinese hamster cell products or other recombinant human or humanized antibodies
  • Patients with mixed epithelial ovarian cancer histology
  • Patients with tumors of low malignant potential
  • History or evidence of upon physical examination of central nervous system (CNS) disease, including history of primary brain tumor or any history of brain metastases, or seizures not controlled with standard medical therapy
  • Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 100 mm Hg; patients with a history of hypertension are permitted
  • Myocardial infarction or unstable angina within 12 months of the first date of bevacizumab therapy
  • New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication; women who have received prior treatment with anthracycline (including doxorubicin and/or liposomal doxorubicin) and have an ejection fraction < 50% will be excluded from the study
  • Grade 1, category 2 or greater, peripheral vascular disease; patient cannot have anything worse than mild, symptomatic claudication with exercise
  • History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of bevacizumab therapy
  • History of pulmonary embolism or deep vein thrombosis in the past 6 months
  • Previous history of malabsorption or other conditions preventing oral treatment
  • Patients who are pregnant or nursing
  • Patients with acute hepatitis or active infection that requires parenteral antibiotics
  • Patients with active bleeding or pathologic conditions that carry a high risk of bleeding such as a known bleeding disorder, coagulopathy or tumor involving the major vessels
  • Patients taking warfarin

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Arm I (carboplatin and paclitaxel)

Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Given IV

Otros nombres:
  • Blastocarbo
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorín
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platinado
  • Ribocarbo
  • JM8

Given IV

Otros nombres:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat

Correlative studies

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida
Experimental: Arm II (oxaliplatin and capecitabine)

Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Correlative studies

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given PO

Otros nombres:
  • Xeloda
  • Ro 09-1978/000

Given IV

Otros nombres:
  • 1-OHP
  • Dacotín
  • Dacplat
  • Eloxatina
  • Ai Heng
  • Aiheng
  • Diaminociclohexano Oxalatoplatino
  • JM-83
  • Oxalatoplatino
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • Elplat
  • JM 83
  • JM83
  • RP54780
  • SR 96669
Experimental: Arm III (carboplatin, paclitaxel, bevacizumab)

Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.

Given IV

Otros nombres:
  • Blastocarbo
  • Carboplat
  • Carboplatino Hexal
  • Carboplatino
  • Carbosina
  • Carbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorín
  • Novoplatino
  • Paraplatino
  • Paraplatino AQ
  • Platinado
  • Ribocarbo
  • JM8

Given IV

Otros nombres:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat

Correlative studies

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given IV

Otros nombres:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anticuerpo monoclonal humanizado anti-VEGF
  • Anticuerpo monoclonal anti-VEGF SIBP04
  • RhuMAb anti-VEGF
  • Bevacizumab awwb
  • Bevacizumab Biosimilar ABP 215
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar MYL-1402O
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • Biosimilar BP102
  • HD204
  • Inmunoglobulina G1 (factor de crecimiento endotelial vascular anti-humano de cadena gamma de rhuMab-VEGF monoclonal de ratón humano), disulfuro con cadena ligera de rhuMab-VEGF monoclonal de ratón humano, dímero
  • Mvasi
  • MYL-1402O
  • Anticuerpo monoclonal anti-VEGF humanizado recombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab Biosimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilar
  • Bevacizumab Biosimilar BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-maly
  • Bevacizumab-onbe
  • TC P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab Biosimilar MB02
  • Bevacizumab-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavás
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305
Experimental: Arm IV (oxaliplatin, capecitabine, bevacizumab)

Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.

Correlative studies

Ancillary studies

Otros nombres:
  • Evaluación de la calidad de vida

Given IV

Otros nombres:
  • Avastin
  • ABP 215
  • Anti-VEGF
  • Anticuerpo monoclonal humanizado anti-VEGF
  • Anticuerpo monoclonal anti-VEGF SIBP04
  • RhuMAb anti-VEGF
  • Bevacizumab awwb
  • Bevacizumab Biosimilar ABP 215
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar CT-P16
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar GB-222
  • Bevacizumab Biosimilar HD204
  • Bevacizumab Biosimilar HLX04
  • Bevacizumab Biosimilar IBI305
  • Bevacizumab biosimilar LY01008
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar Mvasi
  • Bevacizumab Biosimilar MYL-1402O
  • Bevacizumab Biosimilar QL 1101
  • Bevacizumab biosimilar RPH-001
  • Bevacizumab Biosimilar SCT501
  • Bevacizumab Biosimilar Zirabev
  • Bevacizumab-awwb
  • Bevacizumab-bvzr
  • BP102
  • Biosimilar BP102
  • HD204
  • Inmunoglobulina G1 (factor de crecimiento endotelial vascular anti-humano de cadena gamma de rhuMab-VEGF monoclonal de ratón humano), disulfuro con cadena ligera de rhuMab-VEGF monoclonal de ratón humano, dímero
  • Mvasi
  • MYL-1402O
  • Anticuerpo monoclonal anti-VEGF humanizado recombinante
  • rhuMab-VEGF
  • SCT501
  • SIBP 04
  • SIBP-04
  • SIBP04
  • Zirabev
  • Avegra
  • QL1101
  • IBI305
  • Byvasda
  • Bevacizumab Biosimilar QL1101
  • BAT1706
  • BAT 1706
  • BAT-1706
  • BAT1706 Biosimilar
  • Bevacizumab Biosimilar BAT1706
  • Bevacizumab-adcd
  • CT-P16
  • Vegzelma
  • Alymsys
  • ABP-215
  • ABP215
  • Aybintio
  • Bevacizumab-aybi
  • Bevacizumab-equi
  • Bevacizumab-maly
  • Bevacizumab-onbe
  • TC P16
  • CTP16
  • Equidacente
  • Onbevzi
  • Avzivi
  • Bevacizumab Biosimilar MB02
  • Bevacizumab-tnjn
  • FKB 238
  • FKB-238
  • FKB238
  • MB 02
  • MB-02
  • MB02
  • Oyavás
  • PF 06439535
  • PF-06439535
  • PF06439535
  • Bevacizumab-aveg
  • Bevacizumab-byva
  • Bevacizumab-nwgd
  • Jobevne
  • IBI 305
  • IBI-305

Given PO

Otros nombres:
  • Xeloda
  • Ro 09-1978/000

Given IV

Otros nombres:
  • 1-OHP
  • Dacotín
  • Dacplat
  • Eloxatina
  • Ai Heng
  • Aiheng
  • Diaminociclohexano Oxalatoplatino
  • JM-83
  • Oxalatoplatino
  • RP 54780
  • RP-54780
  • SR-96669
  • SR96669
  • Elplat
  • JM 83
  • JM83
  • RP54780
  • SR 96669

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Survival
Periodo de tiempo: Up to five years

Overall survival is defined as the duration of time from study entry to time of death, or the date of last contact.

Up to five years

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Participants With Grade 1 or Higher Non-serious Adverse Effects Assessed by CTCAE Version 4.0
Periodo de tiempo: Every cycle while on treatment, up to 5 years

Grade 1 or higher non-serious adverse events were graded by CTC AE v 4.

Every cycle while on treatment, up to 5 years
Progression-free Survival
Periodo de tiempo: Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.

Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.
Objective Tumor Response
Periodo de tiempo: CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years

Complete and Partial Tumor Response by RECIST 1.1. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v.1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR),.>=30% decrease in the sum of the longest diameter of target lesions; Overall response (OR) = CR + PR

CT scan or MRI if used to follow lesion for measurable disease every other cycle for the first 6 months; then every 3 months x 2; then every 6 months thereafter until disease progression, and any other time clinically indicated, up to 5 years
Patient Reported Neurotoxicity
Periodo de tiempo: baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5

Patient reported neurotoxicity symptoms as measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 4 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative items, reversal was performed prior to score calculation. According to the FACIT measurement system, the Ntx score was the summation of the individual item scores if more than 50% of subscale items were answered. When unanswered items existed, a subscale score was prorated by multiplying the mean of the answered item scores by the number of items in the scale. The Ntx score ranges 0-16 with a large score suggests less neurotoxicity.

baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5
Patient Reported Quality of Life
Periodo de tiempo: baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5

Patient reported quality of life was measured with the Treatment Outcome Index of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-O TOI). The FACT-O TOI is a scale for assessing general QOL of ovarian cancer patients. It consists of three subscales: Physical Well Being (7 items), Functional Well Being (7 items), and Ovarian Cancer subscale (11 items). Each item in the FACT-O TOI was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). For the negative statements (or questions), reversal was performed prior to score calculation. According to the FACIT measurement system, a subscale score was the summation of the individual item scores if more than 50% of subscale items were answered. The FACT-O TOI score ranges 0-100 with a large score suggests better QOL

baseline (pre-treatment), pre cycle 4, post cycle 6, six months post-chemo, end of bevacizumab [BEV] (or 39 weeks after completion of chemotherapy in the non-BEV arms or in those who discontinue BEV), six months after BEV, and years 2, 3, 4, and 5

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Numbers and Percentages of Patients With Mutations in the Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Oncogene
Periodo de tiempo: Baseline

Will be tabulated. Interactions between the mutational status of the KRAS oncogene and treatment will be examined.

Baseline

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Colaboradores

Investigadores

  • Investigador principal: David M Gershenson, NRG Oncology

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

12 de octubre de 2010

Finalización primaria (Actual)

25 de febrero de 2015

Finalización del estudio (Estimado)

12 de marzo de 2027

Fechas de registro del estudio

Enviado por primera vez

4 de marzo de 2010

Primero enviado que cumplió con los criterios de control de calidad

4 de marzo de 2010

Publicado por primera vez (Estimado)

5 de marzo de 2010

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

16 de noviembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • NCI-2011-02516
  • U10CA180868 (Subvención/contrato del NIH de EE. UU.)
  • U10CA027469 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2011-02516 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
  • GOG-0241 (Otro identificador: CTEP)
  • CDR0000667089
  • GOG-0241
  • GOG-0241 (Otro identificador: NRG Oncology)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir